Oivin Guicherit

Critic
DISC Type : C

Director, Translational Biology at Broad Institute of MIT and Harvard

Cambridge, Massachusetts, United States

Overview

A leader with over 25 years of experience in biotechnology and pharmaceuticals, specializing in drug discovery, translational biology, and stem cell therapeutics. He currently serves as the Director of Translational Biology at the Broad Institute, leveraging his Ph. D. from Baylor College of Medicine and postdoctoral work at Stanford University to advance novel therapies.

He shows a strong interest in supporting and connecting innovators, whether in data science or creative fields. His social media activity indicates he is a vocal supporter of Studio Guicherit, an architectural design firm, suggesting an appreciation for design and entrepreneurship.

He is an outspoken advocate for Phenotypic Screening as a powerful method for drug discovery.

Personality Overview

Objective Thinker

Precise

Negotiator

They like to do things independently and don’t look for support from others.  They choose to analyze logically and value facts to emotions. They are quite likely to negotiate on pricing or other key terms.

Topics They Care About

Translational Science
As Director of Translational Biology, his core mission is to bridge deep biological insights with the development of new therapeutics at the Broad Institute's CDoT.
Stem Cell Therapeutics
His background includes senior roles at SanBio and StemoniX, focusing on iPSC and MSC-based regenerative medicines for neurological disorders.
Phenotypic Screening
His professional headline explicitly states a passion for phenotypic screens, a key methodology he has utilized throughout his career in drug discovery.

Media Appearances

Oivin has no verified media appearances

Work History

3-2022
Director, Translational Biology at Broad Institute of MIT and Harvard
1-2021 - 2-2022
Senior Director, Research at SanBio, Inc.
3-2017 - 12-2020
Sr. Director, Drug Discovery at StemoniX
8-2014 - 2-2017
Principal Scientist at Janssen, Pharmaceutical Companies of Johnson and Johnson
1-2013 - 7-2014
Associate Director at Regulus, Inc.

Education

1995 - 1998
Postdoctoral Fellow from Stanford University
1988 - 1994
Doctor of Philosophy (PhD) from Baylor College of Medicine

More Information

Social Presence :

Prographics :

Exp : 27 Location : Cambridge, Massachusetts, United States Job Level : Mid-senior Designation : Director, Translational Biology at Broad Institute of MIT and Harvard
URL has been copied!

Insights For Selling To Oivin

During A Call Or A Meeting

DO's

  • Use phrases like ‘expect X% improvement’, ‘data clearly shows’ etc.
  • Be ready to answer many clarity-seeking questions and requests for information
  • Be ready for penetrating questions and critical examination of your pitch

DONT's

  • Avoid phrases like ‘trust me’, ‘others just love’ etc.
  • Don't give superficial answers, they are easily rattled by them
  • Don’t rush them till they have clearly gotten all the necessary information

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Oivin is

  • Proven ROI, pricing and objective proof points are the factors that sway their decision.
  • Will you ever get a clear answer from Oivin

  • They are comfortable saying no if they are convinced that it is the correct decision.

Insights For Deal Planning

    How fast (or slow) will Oivin move?

  • They are neither the fastest nor the slowest decision makers, they are somewhere in the middle.
  • Can Oivin take some risk or not?

  • They can bear some risk if their analysis backs the decision.

You And Oivin

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.